This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutPathogen CoveragePatient Risk FactorsAntimicrobial Subscription Model PilotDosingDosingDosingPreparation GuideShelf Life and StorageEfficacy & SafetyEfficacy & SafetyMechanism of ActionREPROVE Phase III trial(HAP/VAP)RECLAIM Phase III trial(cIAI)RECAPTURE Phase III trial(cUTI)REPRISE Phase III trial(cIAI and cUTI)Safety and TolerabilityEfficacy and Safety Data for Paediatric PatientsSupport & ResourcesSupport & ResourcesAMS ResourcesSepsisWebinars (Live and On-demand)KOL Videos - ZaviceftaKOL Videos - Gram-negativeKOL Videos - Clinical experienceVideosMaterials

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

ZAVICEFTA® (ceftazidime-avibactam): Broad-spectrum Gram-negative coverage with consistent dosing across indications1–5

View a one page summary of Zavicefta (ceftazidime-avibactam) dosing for both adult and paediatric patients aged 3 months and olderView one page summaryLoading

Adult Patients

Paediatric Patients

ZAVICEFTA (ceftazidime-avibactam) has consistent dosing across indications1,2.

No dose adjustments required in the elderly, patients with mild renal impairment (estimated CrCl >50 to ≤80 mL/min) and those with hepatic impairment1,2

Table 1. Recommended dose for adult patients with estimated CrCL* > 50mL/min1,2

Table 1 footnotes:
§ The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
║There is very limited experience with the use of ZAVICEFTA for more than 14 days.
* The dose of ZAVICEFTA in patients with estimated CrCL ≤50 mL/min should be adjusted according to                 recommended doses. CrCL estimated using the Cockcroft-Gault formula.
† To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be                contributing to the infectious process.
‡ To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are       known or suspected to be contributing to the infectious process.

No dosage adjustment is required in:
  • The elderly
  • Patients with mild renal impairment (estimated CrCL from >50 to ≤80 mL/min)
  • Patients with hepatic impairment
Table 2. Recommended dose adjustments in adult patients with estimated CrCL* ≤ 50 mL/min1,2​​​​​​

Table 2 footnotes:
* CrCL estimated using the Cockcroft-Gault formula.
† Dose recommendations are based on pharmacokinetic modelling.
‡ Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on                    haemodialysis days should occur after completion of haemodialysis.
§ Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only.

Explore more

Abbreviations

cIAI, complicated intra-abdominal infection; CrCL, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end stage renal disease; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; AMR, Antimicrobial Resistance; PK/PD, pharmacokinetics/pharmacodynamics.

References1.ZAVICEFTA. Summary of Product Characteristics (Great Britain)2.ZAVICEFTA. Summary of Product Characteristics (Northern Ireland)3.Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–74.Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–95.Mazuski JE, et al. Surg Infect 2017;18:1–76Prescribing informationClick here for Precribing Information for Zavicefta® (ceftazidime and avibactam)

 
Zyvox® (linezolid)Zyvox (linezolid) 2mg/ml Solution for InfusionZyvox (linezolid) 600mg Film-Coated TabletsZyvox (linezolid) 100mg/5ml Granules for Oral SuspensionDaptomycinGreat BritainDaptomycin 350mg Powder for solution for injection/infusionDaptomycin 500mg Powder for solution for injection/infusionNorthern IrelandDaptomycin 350 & 500mg  powder for solution for injection/infusion
PP-ZVA-GBR-1777. April 2023.
​​​​​​Table 3. Recommended dose for paediatric patients1,5 with estimated CrCL* > 50 mL/min/1.73m2

When treating for cIAI, cUTI, HAP/VAP or LTO, to be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process. 
When treating for cIAI or LTO, to be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.

Table 3 footnotes:
*  CrCL estimated using the Schwartz bedside formula.
¶ The total treatment duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
ǁ There is very limited experience with the use of ZAVICEFTA for more than 14 days.
**There is limited experience with the use of ZAVICEFTA in paediatric patients 3 months to < 6 month.

Table 4. Recommended dose for paediatric patients5 with estimated CrCL* ≤ 50 mL/min/1.73m2 

Table 4 footnotes:
*CrCL estimated using the Schwartz bedside formula
† Dose recommendations are based on pharmacokinetic modelling. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only
**Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis

Table 5. Recommended dose for paediatric patients ≥ 3 months and < 2 years of age1,5 with estimated CrCL* ≤ 50 mL/min/1.73m2

Table 5 footnotes:
*CrCL estimated using the Schwartz bedside formula
†Dose recommendations are based on pharmacokinetic modelling. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only

There is insufficient information to recommend a dosage regimen for paediatric patients < 2 years of age that have a CrCL < 16 mL/min/1.73m2

​​​​Explore more​​​​​​​​​​​​​​​​​​​​​Paediatric Tolerability and Efficacy Data

ZAVICEFTA® (ceftazidime-avibactam): For the treatment of adult and paediatric patients aged 3 months and older at high risk of MDR Gram-negative infections1

Learn more Loading

Abbreviations

cIAI, complicated intra-abdominal infection; CrCL, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end stage renal disease; HAP, hospital-acquired pneumonia; LTO, limited treatment options; VAP, ventilator-associated pneumonia; AMR, Antimicrobial Resistance; PK/PD, pharmacokinetics/pharmacodynamics.

Prescribing information

Click here for Precribing Information for Zavicefta® (ceftazidime and avibactam)

Zyvox® (linezolid)
Zyvox (linezolid) 2mg/ml Solution for Infusion
Zyvox (linezolid) 600mg Film-Coated Tablets
Zyvox (linezolid) 100mg/5ml Granules for Oral Suspension

Daptomycin
Great Britain
Daptomycin 350mg Powder for solution for injection/infusion
Daptomycin 500mg Powder for solution for injection/infusion
Northern Ireland
Daptomycin 350 & 500mg  powder for solution for injection/infusion

References

ZAVICEFTA. Summary of Product Characteristics (Great Britain)Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–7Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9Mazuski JE, et al. Surg Infect 2017;18:1–76ZAVICEFTA. Summary of Product Characteristics (Northern Ireland)
PP-ZVA-GBR-1777. April 2023.
Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials. View tolerability profile LoadingQuick links PK/PD attributes of ceftazidime–avibactam in patients

Federico Pea, Professor of Pharmacology at the University of Bologna, Italy, presents the 'PK/PD attributes of ceftazidime–avibactam in patients'. 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​